According to a newspaper report, the Tübingen biotech company CureVac is investing between 100 and 150 million euros in its planned new production facility.
This is reported by the “Stuttgarter Zeitung” and the “Stuttgarter Nachrichten” (Wednesday) after an interview with CEO Alexander Zehnder. As a result, the facility, which will also be used for our own research, should be ready for use at the beginning of next year. “This will be one of the most modern facilities in the world built exclusively for mRNA technology,” said Zehnder. According to the information, around 100 new jobs will be created. CureVac currently has around 1,100 employees worldwide; around 950 of them in Tübingen.
CureVac is still burdened by the failed development of a corona vaccine. Despite the red numbers, Zehnder was confident in the interview. Investors know that a lot must first be invested in development and clinical studies in the biotech industry. The participation of mainly new investors in the capital increase at the beginning of the year also shows “that there is still interest in our technology and our product pipeline”.
The company recently presented half-year figures with an operating loss of 132.2 million euros. In the same period last year it was 75.6 million euros. CureVac cited, among other things, additional costs associated with the termination of production services for the first-generation Covid-19 vaccine as the reason.
In NASDAQ trading, CureVac shares are moving downwards: at times they are 1.56 percent lower at $6.31.
STUTTGART/TÜBINGEN (dpa-AFX)
Selected leverage products on CureVac
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on CureVac
The leverage must be between 2 and 20
Advertising